This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
6-APB: Difference between revisions
>Oskykins |
>Oskykins |
||
| Line 109: | Line 109: | ||
| [[File:Lolol.png|17px]]''Main articles: [[Research chemicals#Toxicity and harm potential|Research chemicals § Toxicity and harm potential]]'' ''&'' ''[[Responsible use #Hallucinogens|Responsible use § Hallucinogens]]'' | | [[File:Lolol.png|17px]]''Main articles: [[Research chemicals#Toxicity and harm potential|Research chemicals § Toxicity and harm potential]]'' ''&'' ''[[Responsible use #Hallucinogens|Responsible use § Hallucinogens]]'' | ||
|} | |} | ||
Due to only having a short-history of human use, the toxicity and harm potential is not known, though it would be reasonable to assume it is similar to that of [[MDA]] due to their molecular similarity | Due to only having a short-history of human use, the toxicity and harm potential is not known, though it would be reasonable to assume it is similar to that of [[MDA]] due to their molecular similarity. As a potent releaser of serotonin, tolerance builds quickly to the point that the drug eventually loses any positive effects and instead leaves the user in an uncomfortable state of anxious stimulation and dysphoria. | ||
===Short-term health concerns=== | ===Short-term health concerns=== | ||
Short-term physical health risks of 6-APB consumption include dehydration, insomnia, hyperthermia | Short-term physical health risks of 6-APB consumption include dehydration, insomnia, and hyperthermia.<ref>Drug-induced hyperthermia | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2044.1993.tb07423.x/abstract;jsessionid=FC30A9B157A2BAFC81048D8595714565.f02t03</ref>Though it has not been formally studied, like with MDMA, small changes in ambient temperature may cause large changes in 6-APB-induced serotonin neurotoxicity and core body temperature in the rat (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/9634574</ref> and hyponatremia.<ref>Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population | http://jop.sagepub.com/content/20/3/400</ref> Continuous activity without sufficient rest or rehydration may cause body temperature to rise to dangerous levels, and loss of fluid via excessive perspiration puts the body at further risk as the stimulatory and euphoric qualities of the drug may render the user oblivious to their energy expenditure for quite some time. Diuretics such as alcohol may exacerbate these risks further, though this is known to be more of a problem for MDMA than it is 6-APB. | ||
The [[Toxicity::exact toxic dosage is unknown]] | The [[Toxicity::exact toxic dosage is unknown]]. | ||
===Long-term health concerns=== | ===Long-term health concerns=== | ||
The neurotoxicity of 6-APB is controversial. While specifically designed to be less neurotoxic than MDA or MDMA through the avoidance of producing certain metabolic byproducts thought to underlie their toxicity, scientific study has come to the general consensus that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of 6-APB is most certainly neurotoxic in some form, often manifesting as deficits in cognitive, affective and psychomotor function. | The neurotoxicity of 6-APB is controversial. While specifically designed to be less neurotoxic than MDA or MDMA through the avoidance of producing certain metabolic byproducts thought to underlie their toxicity, scientific study has come to the general consensus that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of 6-APB is most certainly neurotoxic in some form, often manifesting as deficits in cognitive, affective and psychomotor function. | ||
As with MDMA, long-term heavy use of 6-APB is likely cardiotoxic and thought to lead to valvulopathy through its actions on the 5-HT2B receptor.<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref> In one study, 28% of long-term users (2-3 doses per week for a mean of 6 years | As with MDMA, long-term heavy use of 6-APB is likely cardiotoxic and thought to lead to valvulopathy through its actions on the 5-HT2B receptor.<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref> In one study, 28% of long-term users (2-3 doses per week for a mean of 6 years with a mean of age 24.3 years) had developed clinically evident valvular heart disease.<ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref> | ||
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug. | It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug. | ||